Law360, New York (September 29, 2009, 5:52 PM ET) -- Irish pharmaceutical company Elan Corp. said Tuesday it had received a subpoena from the U.S. Securities and Exchange Commission requesting details on company disclosures about multiple sclerosis drug Tysabri and an Alzheimer's drug still in development.
In a regulatory filing Tuesday, Elan said it had received a subpoena from the SEC's New York office on Sept. 24, requesting records relating to a July 2008 announcement by Elan and its marketing partner Biogen Idec Inc. of two new cases of patients taking Tysabri contracting a rare and...
Elan Subpoenaed By SEC Over Drug Disclosures
To view the full article, take a free trial now.
